Varian Medical Systems said it posted revenue gains in the first quarter of fiscal 2019 (end-December 28).
Revenue increased to $741 million, up 9% from $678.5 million in the same quarter of 2018. Oncology revenues totaled $702 million, up 8% from last year's $649 million, although operating earnings for the segment decreased by 10%, driven by the effects of U.S.-China tariffs, Varian said.
The company reported net earnings of $103 million, compared with a net loss of $112 million in the first quarter of 2018, according to the firm. The net loss a year ago was a one-time charge incurred as the company moved to repatriate earnings under the 2017 U.S. tax reform.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
